Menu Search
Equities

IDEXX Laboratories Inc

IX1:DUS

IDEXX Laboratories Inc

Actions
  • Price (EUR)451.40
  • Today's Change-12.10 / -2.61%
  • Shares traded11.00
  • 1 Year change+3.51%
  • Beta--
Data delayed at least 15 minutes, as of Apr 17 2024 18:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. Its Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. Its LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve the quality and safety of milk.

  • Revenue in USD (TTM)3.66bn
  • Net income in USD845.04m
  • Incorporated1983
  • Employees11.00k
  • Location
    IDEXX Laboratories IncOne Idexx DriveWESTBROOK 04092-2041United StatesUSA
  • Phone+1 (207) 556-0300
  • Fax+1 (207) 556-4346
  • Websitehttps://www.idexx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.